Akero Therapeutics (AKRO) Competitors $42.85 -0.61 (-1.40%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$42.26 -0.59 (-1.38%) As of 09/15/2025 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AKRO vs. ASND, VTRS, RDY, QGEN, BBIO, MRNA, VRNA, ELAN, ROIV, and RVMDShould you be buying Akero Therapeutics stock or one of its competitors? The main competitors of Akero Therapeutics include Ascendis Pharma A/S (ASND), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), QIAGEN (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry. Akero Therapeutics vs. Its Competitors Ascendis Pharma A/S Viatris Dr. Reddy's Laboratories QIAGEN BridgeBio Pharma Moderna Verona Pharma PLC American Depositary Share Elanco Animal Health Roivant Sciences Revolution Medicines Ascendis Pharma A/S (NASDAQ:ASND) and Akero Therapeutics (NASDAQ:AKRO) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends. Does the media favor ASND or AKRO? In the previous week, Akero Therapeutics had 7 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 16 mentions for Akero Therapeutics and 9 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 1.27 beat Akero Therapeutics' score of 0.48 indicating that Ascendis Pharma A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akero Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend ASND or AKRO? Ascendis Pharma A/S currently has a consensus target price of $244.36, suggesting a potential upside of 25.56%. Akero Therapeutics has a consensus target price of $81.14, suggesting a potential upside of 89.36%. Given Akero Therapeutics' higher probable upside, analysts plainly believe Akero Therapeutics is more favorable than Ascendis Pharma A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ascendis Pharma A/S 0 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 3.00Akero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, ASND or AKRO? Ascendis Pharma A/S has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.24, meaning that its share price is 124% less volatile than the S&P 500. Is ASND or AKRO more profitable? Akero Therapeutics has a net margin of 0.00% compared to Ascendis Pharma A/S's net margin of -54.94%. Ascendis Pharma A/S's return on equity of 0.00% beat Akero Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Ascendis Pharma A/S-54.94% N/A -24.31% Akero Therapeutics N/A -15.84%-14.59% Which has preferable earnings & valuation, ASND or AKRO? Akero Therapeutics has lower revenue, but higher earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Akero Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAscendis Pharma A/S$393.54M30.27-$409.12M-$5.16-37.72Akero TherapeuticsN/AN/A-$252.06M-$2.00-21.43 SummaryAkero Therapeutics beats Ascendis Pharma A/S on 7 of the 12 factors compared between the two stocks. Get Akero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKRO vs. The Competition Export to ExcelMetricAkero TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.48B$3.15B$5.80B$10.17BDividend YieldN/A2.32%5.72%4.61%P/E Ratio-21.4321.2475.0526.39Price / SalesN/A466.71544.00190.24Price / CashN/A44.4425.8129.91Price / Book3.999.6413.436.28Net Income-$252.06M-$53.20M$3.29B$270.38M7 Day Performance-3.97%0.07%0.08%1.89%1 Month Performance-13.22%4.27%4.61%6.01%1 Year Performance60.07%9.62%75.02%25.26% Akero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKROAkero Therapeutics3.8895 of 5 stars$42.85-1.4%$81.14+89.4%+56.7%$3.48BN/A-21.4330Analyst DowngradeASNDAscendis Pharma A/S3.191 of 5 stars$205.22-0.3%$244.36+19.1%+63.2%$12.60B$393.54M-39.771,017Positive NewsVTRSViatris1.6375 of 5 stars$10.48-0.2%$10.40-0.8%-17.7%$12.24B$14.74B-3.6132,000RDYDr. Reddy's Laboratories2.2866 of 5 stars$14.27-0.5%$16.95+18.8%-9.0%$11.97B$3.81B21.6127,811QGENQIAGEN4.4448 of 5 stars$47.62+0.1%$49.69+4.4%+0.7%$10.57B$1.98B28.135,765Positive NewsBBIOBridgeBio Pharma4.4092 of 5 stars$54.29+1.7%$63.35+16.7%+96.6%$10.20B$221.90M-13.27400Analyst ForecastMRNAModerna4.5366 of 5 stars$24.83-1.2%$42.88+72.7%-65.0%$9.78B$3.24B-3.305,800VRNAVerona Pharma PLC American Depositary Share2.3188 of 5 stars$106.300.0%$109.00+2.5%+257.2%$9.20B$42.28M-107.3730Positive NewsELANElanco Animal Health2.6271 of 5 stars$19.02+3.2%$17.33-8.9%+28.7%$9.16B$4.44B22.129,000ROIVRoivant Sciences3.1466 of 5 stars$12.91-0.1%$16.38+26.8%+16.8%$8.82B$29.05M-18.44860Positive NewsRVMDRevolution Medicines4.1932 of 5 stars$41.06+1.4%$72.00+75.4%+5.7%$7.57B$11.58M-9.12250Insider TradeAnalyst Revision Related Companies and Tools Related Companies Ascendis Pharma A/S Alternatives Viatris Alternatives Dr. Reddy's Laboratories Alternatives QIAGEN Alternatives BridgeBio Pharma Alternatives Moderna Alternatives Verona Pharma PLC American Depositary Share Alternatives Elanco Animal Health Alternatives Roivant Sciences Alternatives Revolution Medicines Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKRO) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AKRO Stock Alerts